UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): JANUARY 24, 2003
IMMUNOGEN, INC.
-----------------------------------------------------
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 0-17999 04-2726691
-------------------------------------------------------------------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
128 SIDNEY STREET, CAMBRIDGE, MA 02139
--------------------------------------------------
(Address of principal executive offices) (Zip Code)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (617) 995-2500
------------------------------------------------------------------
ITEM 5. OTHER EVENTS
On January 24, 2003, ImmunoGen, Inc. announced that the Company has regained the
development and commercialization rights for cantuzumab mertansine (huC242-DM1)
from GlaxoSmithKline plc. The press release announcing this event is
incorporated herein by reference and filed as Exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits
EXHIBIT NO. EXHIBIT
----------- -------
99.1 The Registrant's Press Release dated
January 24, 2003.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
IMMUNOGEN, INC.
----------------
(Registrant)
Date: JANUARY 24, 2003 /s/ GREGG D. BELOFF
-------------------
Gregg D. Beloff
Chief Financial Officer and
Vice President, Finance
3
EXHIBIT INDEX
EXHIBIT NO. EXHIBIT
----------- -------
99.1 The Registrant's Press Release dated
January 24, 2003.